E
XORTX Therapeutics Inc. XRTX
$1.27 $0.021.60%
Recommendation
Sell
Prev Close
$1.25
Volume
3,611,438
Avg Vol (90D)
69,562
Market Cap
$4.37M
Dividend & Yield
--
52-Week Range
$1.06 - $7.00
P/E (TTM)
--
EPS (TTM)
-$0.0441
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program
1/6/2025 - TipRanks Financial Blog
Xortx Therapeutics announces launch of late stage program to treat gout
1/6/2025 - The Fly
XORTX Adds Late Stage Gout Program to Pipeline
1/6/2025 - Globe Newswire
XORTX Therapeutics Welcomes New CFO Dr. Bumby
12/19/2024 - TipRanks Financial Blog
Xortx Therapeutics appoints Bumby as Chief Financial Officer
12/19/2024 - The Fly
XORTX Strengthens Executive Team
12/19/2024 - Globe Newswire
Xortx Therapeutics announces presentation at Rare, Genetic Disease Summit
12/12/2024 - The Fly
XORTX Announces Presentation at the Rare and Genetic Disease Summit
12/12/2024 - Globe Newswire
XORTX Therapeutics files to sell 810,810 common shares for holders
11/15/2024 - SeekingAlpha.com: All News
Xortx Therapeutics files to sell 810,810 common shares for holders
11/15/2024 - TipRanks Financial Blog
Xortx Therapeutics files to sell 810,810 common shares for holders
11/15/2024 - The Fly
XORTX Therapeutics Inc. Faces Financial Challenges
11/15/2024 - TipRanks Financial Blog
Xortx Therapeutics announces presentation of sponsored study at ASN Kidney Week
10/24/2024 - The Fly
XORTX Sponsored Study Presented at the American Society of Nephrology Kidney Week 2024
10/24/2024 - Globe Newswire
XORTX Secures $1.5 Million in Latest Offering
10/18/2024 - TipRanks Financial Blog
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
10/18/2024 - Globe Newswire
XORTX Therapeutics stock falls after pricing $1.5M capital raise
10/17/2024 - Seeking Alpha - Healthcare
Xortx Therapeutics to sell 810,810 shares at $1.85 in registered direct offering
10/17/2024 - The Fly
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
10/17/2024 - Globe Newswire
Xortx Therapeutics initiates precision medicine program
10/9/2024 - TipRanks Financial Blog
Xortx Therapeutics initiates precision medicine program
10/9/2024 - The Fly
XORTX Initiates Precision Medicine Program
10/9/2024 - Globe Newswire
XORTX Therapeutics Shareholders Approve Key Decisions
9/13/2024 - TipRanks Financial Blog
Xortx Therapeutics announces results of Annual, Special Meeting
9/13/2024 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$2.76M
EBIT (TTM)
-$2.84M
Net Income (TTM)
-$736.60K
Balance Sheet
Total Assets (Q)
$3.85M
Total Debt (Q)
$61.50K
Total Liabilities (Q)
$1.72M
Book Value Per Share (Q)
$0.7348
Cash Flow
Cash from Operations (TTM)
-$4.09M
Cash from Investing (TTM)
-$44.70K
Cash from Financing (TTM)
$1.36M
Net Change in Cash (TTM)
-$2.77M
Filings
Filing Date
Friday, November 15, 2024
Period Date
Monday, September 30, 2024
Next Filing
Beginning of April (est)
Price History
Loading...
Beta
-1.13
7-Day Total Return
8.56%
30-Day Total Return
4.96%
60-Day Total Return
-41.47%
90-Day Total Return
-46.64%
Year to Date Total Return
8.56%
1-Year Total Return
-42.01%
2-Year Total Return
-83.20%
3-Year Total Return
-92.84%
5-Year Total Return
-88.43%
52-week Low
Dec 26, 2024 - $1.06
52-week High
Mar 07, 2024 - $7.00
Valuation
Market Cap
$4.37M - Nano Cap
Enterprise Value
$2.27M
Price/Sales (TTM)
--
Price/Book (Q)
1.70
Dividends and Shares
Shares Outstanding
2.90M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.xortx.com
Phone Number
403 455 7727
Address
3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Country
Canada
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin... more
NASDAQ 01/14/2025 3:59PM Eastern Quotes delayed
Weiss Ratings